{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:24:53Z","timestamp":1774538693266,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.contraception.2009.12.005","type":"journal-article","created":{"date-parts":[[2010,1,16]],"date-time":"2010-01-16T09:16:06Z","timestamp":1263633366000},"page":"391-400","source":"Crossref","is-referenced-by-count":17,"title":["An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol\/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables"],"prefix":"10.1016","volume":"81","author":[{"given":"Ulrich H.","family":"Winkler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"R\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kornelia","family":"H\u00f6schen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2009.12.005_bb0005","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/ije\/19.4.931","article-title":"Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism","volume":"19","author":"Gerstman","year":"1990","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.contraception.2009.12.005_bb0010","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"Gerstman","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.contraception.2009.12.005_bb0015","first-page":"91","article-title":"Venous thromboembolism in relation to oral contraceptive use","volume":"69","author":"Helmrich","year":"1987","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.12.005_bb0020","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease","volume":"346","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2009.12.005_bb0025","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(95)91929-5","article-title":"Enhancement by factor V. Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen","volume":"346","author":"Bloemenkamp","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2009.12.005_bb0030","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2009.12.005_bb0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.312.7023.83","article-title":"Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women","volume":"312","author":"Spitzer","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2009.12.005_bb0040","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1365-2125.2000.00198.x","article-title":"A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives","volume":"49","author":"Farmer","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2009.12.005_bb0045","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/humrep\/14.6.1500","article-title":"Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database","volume":"14","author":"Todd","year":"1999","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2009.12.005_bb0050","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/S0010-7824(00)00148-7","article-title":"Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism","volume":"62","author":"Winkler","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0055","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2009.12.005_bb0060","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2009.12.005_bb0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00044011-200222040-00002","article-title":"Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg\/ethinylestradiol 0.03 mg (Belara\u00ae). Results of a post-marketing surveillance study","volume":"22","author":"Schramm","year":"2002","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.contraception.2009.12.005_bb0070","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0010-7824(02)00536-X","article-title":"A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties","volume":"67","author":"Schramm","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0010-7824(98)00008-0","article-title":"Efficacy and safety of the new antiandrogenic oral contraceptive Belara","volume":"57","author":"Zahradnik","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.contraception.2007.12.007","volume":"77","author":"Zahradnik","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0085","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00003495-200464070-00005","article-title":"Ethinylestradiol\/chlormadinone acetate","volume":"64","author":"Curran","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.contraception.2009.12.005_bb0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000051701","article-title":"Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE\/CMA (Belara) and EE\/LNG (Microgynon)","volume":"203","author":"Worret","year":"2001","journal-title":"Dermatology"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2009.12.005_bb0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/13625180500434897","article-title":"Belara \u2014 a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea","volume":"10","author":"Zahradnik","year":"2005","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2009.12.005_bb0100","first-page":"164","article-title":"Recommendations for oral contraception. 20th Professional Meeting of the Zurich Discussion Group, April 1998","volume":"38","author":"Birkhauser","year":"1998","journal-title":"Gynakol Geburtshilfliche Rundsch"},{"key":"10.1016\/j.contraception.2009.12.005_bb0105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/bmj.2.5703.231","article-title":"Combined oral contraceptives. A statement by the Committee on Safety of Drugs","volume":"2","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.contraception.2009.12.005_bb0110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/bmj.2.5704.293","article-title":"R.C.O.G. statement on oral contraceptives","volume":"2","author":"Jeffcoate","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.contraception.2009.12.005_bb0115","first-page":"172","article-title":"Recommendations for oral contraception. 24th meeting of the \"Zurich Discussion Circle\"","volume":"40","author":"Birkhauser","year":"2000","journal-title":"Gynakol Geburtshilfliche Rundsch"},{"key":"10.1016\/j.contraception.2009.12.005_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0010-7824(96)00137-0","article-title":"Shorter pill-free interval in combined oral contraceptives decreases follicular development","volume":"54","author":"Spona","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0015-0282(99)00205-8","article-title":"Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity","volume":"72","author":"Sullivan","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2009.12.005_bb0130","series-title":"Laboratory techniques in thrombosis - a manual. Second revised edition of ECAT Assay Procedures","author":"Jespersen","year":"1999"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2009.12.005_bb0140","first-page":"S5","article-title":"Report of the expert committee on the diagnosis and classification of diabetes mellitus","volume":"26","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.contraception.2009.12.005_bb0145","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.contraception.2009.12.005_bb0150","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.contraception.2004.12.005","article-title":"Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism","volume":"71","author":"Klipping","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0155","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0010-7824(02)00476-6","article-title":"The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study","volume":"67","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0160","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.contraception.2005.09.015","article-title":"A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol","volume":"73","author":"Kluft","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09513590500430328","article-title":"Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 microg gestodene on hemostatic parameters","volume":"22","author":"Aldrighi","year":"2006","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2009.12.005_bb0170","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.contraception.2005.01.006","article-title":"A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel","volume":"72","author":"Jespersen","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0175","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0180","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0010-7824(97)00010-3","article-title":"Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin. UK Desogen Study Group","volume":"55","author":"Crook","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.contraception.2003.11.003","article-title":"A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles","volume":"69","author":"Gaspard","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0010-7824(00)00196-7","article-title":"Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel","volume":"63","author":"Knopp","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0195","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.298.6680.1049","article-title":"Oral contraceptives and lipids","volume":"298","author":"Fotherby","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2009.12.005_bb0200","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3109\/00016349409013416","article-title":"Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone","volume":"73","author":"Akerlund","year":"1994","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2009.12.005_bb0205","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0002-9378(98)70291-1","article-title":"Metabolic and endocrine effects of the desogestrel-containing oral contraceptive Mircette","volume":"179","author":"Berga","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2009.12.005_bb0210","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2796.2001.00906.x","article-title":"Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation","volume":"250","author":"Kemmeren","year":"2001","journal-title":"J Intern Med"},{"key":"10.1016\/j.contraception.2009.12.005_bb0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0010-7824(01)00316-X","article-title":"An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables","volume":"65","author":"Endrikat","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0220","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.contraception.2003.10.004","article-title":"Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism","volume":"69","author":"Scharnagl","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0225","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0010-7824(02)00537-1","article-title":"A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism","volume":"67","author":"Gaspard","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0230","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0010-7824(02)00415-8","article-title":"Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism","volume":"66","author":"Ludicke","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2009.12.005_bb0235","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003495-200363050-00003","article-title":"Progestogens with antiandrogenic properties","volume":"63","author":"Raudrant","year":"2003","journal-title":"Drugs"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078240900523X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078240900523X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T05:36:38Z","timestamp":1558762598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001078240900523X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S001078240900523X"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2009.12.005","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}